礼来AD新药获批,剑指国内千亿市场

健识局
18 Dec 2024

12月18日,礼来宣布多奈单抗注射液获中国药监局批准上市,掀起行业涟漪。五个月前,该药才刚刚在美国批准用于治疗成人因阿尔茨海默病引起的轻度认知功能障碍和阿尔茨海默病轻度痴呆(AD),此次中国获批同一适应症。据悉,多奈单抗可与β淀粉样蛋白亚型N3pG结合,促进患者大脑中淀粉样蛋白斑块的清除。礼来表示,多奈单抗注射液是第一款且唯一有证据支持,在清除淀粉样蛋白斑块后可停药的靶向淀粉样蛋白的疗法。该药可以...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10